Abbott Laboratories (NYSE:ABT) VP John Jr. Mccoy Sells 585 Shares of Stock

Abbott Laboratories (NYSE:ABT) VP John Jr. Mccoy sold 585 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $67,614.30. Following the completion of the sale, the vice president owned 24,628 shares in the company, valued at $2,846,504.24. This represents a 2.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Abbott Laboratories Stock Performance

Shares of NYSE ABT opened at $113.55 on Wednesday. The business has a fifty day simple moving average of $116.90 and a 200 day simple moving average of $125.00. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19. Abbott Laboratories has a one year low of $105.27 and a one year high of $141.23. The firm has a market capitalization of $197.31 billion, a price-to-earnings ratio of 30.52, a PEG ratio of 1.82 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.50. The company had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period last year, the company posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Sell-side analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio is 67.74%.

Institutional Trading of Abbott Laboratories

Several hedge funds and other institutional investors have recently modified their holdings of ABT. MidAtlantic Capital Management Inc. acquired a new stake in Abbott Laboratories in the 4th quarter valued at approximately $25,000. Cornerstone Financial Management LLC acquired a new stake in shares of Abbott Laboratories in the fourth quarter valued at approximately $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in shares of Abbott Laboratories in the fourth quarter worth $26,000. Abound Financial LLC bought a new position in Abbott Laboratories in the fourth quarter valued at $26,000. Finally, Harbor Capital Advisors Inc. bought a new stake in Abbott Laboratories during the 4th quarter worth about $27,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: FDA approval of the redesigned CardioMEMS Hero remote heart‑failure monitor — a smaller, lighter reader aimed at improving patient convenience and clinician workflows — strengthens Abbott’s position in heart‑failure management and could increase adoption and revenue over time. How FDA Approval of CardioMEMS Hero Remote Monitor At Abbott (ABT) Has Changed Its Investment Story
• Neutral Sentiment: Multiple insider sales disclosed (several senior/executive officers sold small blocks of shares on Mar. 2). The transactions were modest relative to their remaining holdings, suggesting routine portfolio management rather than a clear signal of company deterioration. John A. Jr. Mccoy Insider Sale
• Negative Sentiment: Near-term earnings pressure: Q4 EPS met estimates but revenue came in below consensus ($11.46B vs. ~$11.80B), which, together with recent softer quarterly trends, has left analysts cautious and weighed on the stock. Abbott (ABT) Stock Sinks As Market Gains: Here’s Why
• Negative Sentiment: Shares have underperformed the market over the past six months amid disappointing near‑term results and investor skepticism, which increases sensitivity to any incremental downside news. 2 Reasons to Like ABT and 1 to Stay Skeptical

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on ABT shares. Oppenheimer lowered their price target on shares of Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Daiwa Securities Group decreased their price objective on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a research note on Friday, January 30th. Evercore cut their target price on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Citigroup lowered their price target on Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating for the company in a research note on Friday, January 23rd. Finally, Leerink Partners decreased their price objective on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a report on Friday, January 30th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $137.05.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.